ReachRxResearch
Home
Research
Sign Up
Implementing Genetic Cascade Testing for Familial Hypercholesterolemia in Primary Care: Patient and General Practitioner Experiences
Back to Research Hub
  1. Home
  2. Research Hub
  3. Implementing Genetic Cascade Testing for…

Implementing Genetic Cascade Testing for Familial Hypercholesterolemia in Primary Care: Patient and General Practitioner Experiences

International Journal of Behavioral Medicine·August 19Open Access
Psychology, ClinicalLimited evidenceFamilial HypercholesterolemiaMixed-Methods StudyGenetic Cascade TestingMixed

Summary

View source

What was studied

This mixed-methods study explored barriers and facilitators to FH genetic cascade testing in primary care, using semi-structured interviews with FH-diagnosed adults and parents of affected children (n=20), plus open-ended GP questionnaires (n=12), following delivery of the EDIFICE program in general practice.

Key findings

Five key themes emerged: knowledge gaps about FH, communication and testing challenges, emotional distress at diagnosis, GPs' limited professional confidence, and system-level barriers — with both patients and GPs calling for better educational resources and streamlined referral pathways.

Study limitations

Small, potentially self-selected sample (20 patients, 12 GPs) limits generalizability. Study is set within a single program (EDIFICE), so findings may not transfer to other healthcare systems. GP data came from open-ended questionnaires rather than in-depth interviews, which may reduce depth of professional insights.

Clinical implications

GPs should seek FH-specific training and establish clear referral links with lipid clinics before undertaking cascade testing. Providing patients with plain-language FH resources at diagnosis can reduce distress and improve understanding of the need for family testing.

Caveats

  • Publication date (2026-08-19) is in the future relative to the PDF creation date (2025-12-18), suggesting possible ahead-of-print or early online status; findings should be interpreted as preliminary until final publication is confirmed.
  • Sample size is small (20 patients, 12 GPs) and all participants were drawn from a single Australian program (EDIFICE/Royal Perth Hospital), which may limit generalizability to other health systems.
  • The full text provided appears to be the GP survey instrument rather than a complete published manuscript, so some methodological details (e.g., participant demographics, detailed thematic analysis data) could not be verified from the source.

Related Questions

Explore related topics

What are the main barriers to FH cascade testing in primary care and how can they be overcome?How should GPs counsel patients before and after familial hypercholesterolemia genetic testing?What educational tools or training programs help GPs manage familial hypercholesterolemia?

Publication Details

Year
2026
Journal
International Journal of Behavioral Medicine
Sample Size
n=32
Source
View article
Keep scrolling
More content below.
Up Next